Purdue's multi-billion dollar settlement in jeopardy after federal judge tosses deal; BioMarin announces global gene therapy collaboration
Well, Purdue Pharma’s multi-billion dollar opioid settlement is now in jeopardy — a federal judge just said no.
Colleen McMahon, a judge on the US District Court for the Southern District of New York, said that the settlement, which would dissolve Purdue Pharma and was approved in September by a bankruptcy judge, should not go forward because it releases the company’s owners, members of the billionaire Sackler family, from liability in civil opioid-related cases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.